The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome
The aim of our study was to study the relationship between the CYP2C19 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome in order to develop algorithms for optimizing the therapy of diazepam to reduce the risk of dose-dependent adverse drug rea...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian State Medical University (Tomsk)
2020-01-01
|
| Series: | Бюллетень сибирской медицины |
| Subjects: | |
| Online Access: | https://bulletin.ssmu.ru/jour/article/view/2564 |
| _version_ | 1827991503099658240 |
|---|---|
| author | V. Yu. Skryabin M. S. Zastrozhin E. A. Grishina K. A. Ryzhikova V. V. Shipitsyn I. V. Barna T. E. Galaktionova A. S. Sorokin E. A. Bryun D. A. Sychev |
| author_facet | V. Yu. Skryabin M. S. Zastrozhin E. A. Grishina K. A. Ryzhikova V. V. Shipitsyn I. V. Barna T. E. Galaktionova A. S. Sorokin E. A. Bryun D. A. Sychev |
| author_sort | V. Yu. Skryabin |
| collection | DOAJ |
| description | The aim of our study was to study the relationship between the CYP2C19 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome in order to develop algorithms for optimizing the therapy of diazepam to reduce the risk of dose-dependent adverse drug reactions and pharmacoresistance.Materials and methods. The study was conducted on 30 Russian male patients suffering from alcohol withdrawal syndrome. For the treatment of anxiety, fear and emotional tension, patients received diazepam in injections at a dosage of 30,0 mg / day for 5 days. Genotyping was performed by real-time polymerase chain reaction with allele-specific hybridization. The efficacy and safety assessment was performed using psychometric scales and scales for assessing the severity of adverse drug reactions: the Clinical Institute Withdrawal Assessment for Alcohol scale, the visual-analogue scale of the craving for alcohol, and the side-effect scale.Results. Based on the results of the study, we revealed the differences in the efficacy of therapy in patients with different CYP2C19 -806C>T genotypes: (CC) –12,0 [–15,0; –8,0], (CT + TT) –7.0 [–14,0; –5,0], p = 0,001. The scores on the UKU scale, which was used to evaluate the safety of therapy, were also different: (CC) 8,0 [6,0; 12,0], (CT + TT) 6,0 [6,0; 12,0], p = 0,006.Conclusion. The relationships between the CYP2C19 genetic polymorphism and the efficacy and safety of diazepam were demonstrated. This should be taken into consideration when prescribing this drug to such patients in order to reduce the risk of adverse drug reactions and pharmacoresistance. |
| first_indexed | 2024-04-10T01:06:08Z |
| format | Article |
| id | doaj.art-35151813c946415292f1bf2ab1486e4b |
| institution | Directory Open Access Journal |
| issn | 1682-0363 1819-3684 |
| language | English |
| last_indexed | 2024-04-10T01:06:08Z |
| publishDate | 2020-01-01 |
| publisher | Siberian State Medical University (Tomsk) |
| record_format | Article |
| series | Бюллетень сибирской медицины |
| spelling | doaj.art-35151813c946415292f1bf2ab1486e4b2023-03-13T09:58:25ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842020-01-0118411912610.20538/1682-0363-2019-4-119-1261572The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndromeV. Yu. Skryabin0M. S. Zastrozhin1E. A. Grishina2K. A. Ryzhikova3V. V. Shipitsyn4I. V. Barna5T. E. Galaktionova6A. S. Sorokin7E. A. Bryun8D. A. Sychev9Московский научно-практический центр (МНПЦ) наркологии Департамента здравоохранения Москвы (ДЗМ)1Московский научно-практический центр (МНПЦ) наркологии Департамента здравоохранения Москвы (ДЗМ); Российская медицинская академия непрерывного профессионального образования (РМАНПО)Российская медицинская академия непрерывного профессионального образования (РМАНПО)Российская медицинская академия непрерывного профессионального образования (РМАНПО)Московский научно-практический центр (МНПЦ) наркологии Департамента здравоохранения Москвы (ДЗМ)Московский научно-практический центр (МНПЦ) наркологии Департамента здравоохранения Москвы (ДЗМ)Московский научно-практический центр (МНПЦ) наркологии Департамента здравоохранения Москвы (ДЗМ)Московский научно-практический центр (МНПЦ) наркологии Департамента здравоохранения Москвы (ДЗМ)Московский научно-практический центр (МНПЦ) наркологии Департамента здравоохранения Москвы (ДЗМ); Российская медицинская академия непрерывного профессионального образования (РМАНПО)Российская медицинская академия непрерывного профессионального образования (РМАНПО)The aim of our study was to study the relationship between the CYP2C19 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome in order to develop algorithms for optimizing the therapy of diazepam to reduce the risk of dose-dependent adverse drug reactions and pharmacoresistance.Materials and methods. The study was conducted on 30 Russian male patients suffering from alcohol withdrawal syndrome. For the treatment of anxiety, fear and emotional tension, patients received diazepam in injections at a dosage of 30,0 mg / day for 5 days. Genotyping was performed by real-time polymerase chain reaction with allele-specific hybridization. The efficacy and safety assessment was performed using psychometric scales and scales for assessing the severity of adverse drug reactions: the Clinical Institute Withdrawal Assessment for Alcohol scale, the visual-analogue scale of the craving for alcohol, and the side-effect scale.Results. Based on the results of the study, we revealed the differences in the efficacy of therapy in patients with different CYP2C19 -806C>T genotypes: (CC) –12,0 [–15,0; –8,0], (CT + TT) –7.0 [–14,0; –5,0], p = 0,001. The scores on the UKU scale, which was used to evaluate the safety of therapy, were also different: (CC) 8,0 [6,0; 12,0], (CT + TT) 6,0 [6,0; 12,0], p = 0,006.Conclusion. The relationships between the CYP2C19 genetic polymorphism and the efficacy and safety of diazepam were demonstrated. This should be taken into consideration when prescribing this drug to such patients in order to reduce the risk of adverse drug reactions and pharmacoresistance.https://bulletin.ssmu.ru/jour/article/view/2564фармакогенетикабензодиазепиныдиазепамбиотрансформацияперсонализированная медицинаcyp2c19синдром отмены алкоголя |
| spellingShingle | V. Yu. Skryabin M. S. Zastrozhin E. A. Grishina K. A. Ryzhikova V. V. Shipitsyn I. V. Barna T. E. Galaktionova A. S. Sorokin E. A. Bryun D. A. Sychev The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome Бюллетень сибирской медицины фармакогенетика бензодиазепины диазепам биотрансформация персонализированная медицина cyp2c19 синдром отмены алкоголя |
| title | The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome |
| title_full | The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome |
| title_fullStr | The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome |
| title_full_unstemmed | The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome |
| title_short | The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome |
| title_sort | relationship between the cyp2c19 17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome |
| topic | фармакогенетика бензодиазепины диазепам биотрансформация персонализированная медицина cyp2c19 синдром отмены алкоголя |
| url | https://bulletin.ssmu.ru/jour/article/view/2564 |
| work_keys_str_mv | AT vyuskryabin therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT mszastrozhin therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT eagrishina therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT karyzhikova therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT vvshipitsyn therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT ivbarna therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT tegalaktionova therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT assorokin therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT eabryun therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT dasychev therelationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT vyuskryabin relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT mszastrozhin relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT eagrishina relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT karyzhikova relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT vvshipitsyn relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT ivbarna relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT tegalaktionova relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT assorokin relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT eabryun relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome AT dasychev relationshipbetweenthecyp2c1917geneticpolymorphismandtheefficacyandsafetyofdiazepaminpatientswithalcoholwithdrawalsyndrome |